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E-mail: moj2005@med.cornell.eduCancer therapy utilizing adoptive transfer of chimeric antigen
receptor (CAR) T cells has demonstrated remarkable clinical
outcomes in hematologic malignancies. However, CAR T cell
application to solid tumors has had limited success, partly
due to the lack of tumor-specific antigens and an immune-sup-
pressive tumor microenvironment. From the tumor tissues of
gastric cancer patients, we found that intercellular adhesion
molecule 1 (ICAM-1) expression is significantly associated
with advanced stage and shorter survival. In this study, we
report a proof-of-concept study using ICAM-1-targeting
CAR T cells against gastric cancer. The efficacy of ICAM-1
CAR T cells showed a significant correlation with the level of
ICAM-1 expression in target cells in vitro. In animal models
of human gastric cancer, ICAM-1-targeting CAR T cells
potently eliminated tumors that developed in the lungs, while
their efficacy was more limited against the tumors in the peri-
toneum. To augment CAR T cell activity against intraperito-
neal tumors, combinations with paclitaxel or CAR activation-
dependent interleukin (IL)-12 release were explored and found
to significantly increase anti-tumor activity and survival
benefit. Collectively, ICAM-1-targeting CAR T cells alone or
in combination with chemotherapy represent a promising
strategy to treat patients with ICAM-1+ advanced gastric
cancer.
INTRODUCTION
Gastric cancer (GC) is the fifth most common cancer and the third
leading cause of death in the world.1 Surgical resection combined
with adjuvant chemotherapy is the only method for treating localized
GC.2,3 Moreover, more than 50% of GC patients progress to an
advanced stage with dismal prognosis.4,5 The treatment of patients
with locally advanced andmetastatic disease is currently based on sys-
temic therapy or palliative supportive care with a median overall sur-
vival of 1 year.6 The targeted agent for human epidermal growth fac-
tor receptor 2 (HER2), trastuzumab, has been used with modest
efficacy for advanced disease in HER2+ patients, which accounts for
less than 20% of patients with gastric tumors.7 In addition, patients
with peritoneal carcinomatosis are largely excluded from trastuzu-Molecular Ther
This is an open access article under the CC BY-NC-mab therapy due to very low levels of HER2 expression, and show
amedian survival of 6 months due to a lack of any other effective ther-
apeutic modalities.8 Therapies targeting vascular endothelial factor
(VEGF) are also being explored with evidence of improved overall
survival by 2 months.9 Yet, there is still a crucial need to develop
new treatment modalities for GC.
Cancer immunotherapy with antibodies that block the interaction be-
tween programmed death-1 (PD-1) and its ligand (PD-L1) has pro-
duced durable responses in some types of solid tumors, particularly
melanoma and lung cancer.10,11 In advanced GC, however, the effi-
cacy of immune checkpoint inhibitors has been marginal, with objec-
tive response rates of 7%–26% across varying GC populations.12 CAR
T cell therapy is another type of cancer immunotherapy that has sub-
stantially improved outcomes in patients with hematologic malig-
nancies.13 In the setting of GC, a number of preclinical and clinical
studies have examined the efficacy of CAR T cells that target antigens
such as HER2, carcinoembryonic antigen (CEA), epithelial cell adhe-
sion molecule (EpCAM), mesothelin (MSLN), and claudin 18.2
(CLDN18.2).14–18 However, the application of CAR T cell therapy
for solid tumors in clinical studies is associated with limited success,
partly due to the lack of tumor-specific antigens as well as inhibitory
factors in the tumor microenvironments.19,20
Intercellular adhesionmolecule 1 (ICAM-1) is a cell surface glycopro-
tein receptor involved in cell-cell and cell-matrix adhesive interac-
tions.21 ICAM-1 is overexpressed in several cancers, including GC,
and the survival rate of GC patients with high ICAM-1 expression
is worse than that of those with low expression.22 Recently, we re-
ported the robust results of CAR T cell therapy targeting ICAM-1
in thyroid cancer models. A single administration of ICAM-1 CARapy: Oncolytics Vol. 18 September 2020 ª 2020 The Author(s). 587
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1. Baseline Characteristics of Patients According to ICAM-1 Expression





male 56 (60.2) 37 (39.8)
female 30 (73.2) 11 (26.8)
Lauren’s classification 0.157
intestinal 32 (69.6) 14 (30.4)
diffuse 43 (57.3) 32 (42.7)
mixed and
unclassifiable
11 (84.6) 2 (15.4)
HER2 status 0.331
negative 78 (62.9) 46 (37.1)




58 (68.2) 27 (31.8)
total
gastrectomy
28 (57.1) 21 (42.9)
Stage 0.002
II 43 (79.6) 11 (20.4)
III 43 (53.8) 37 (46.3)
T stage 0.102
1 2 (66.7) 1 (33.3)
2 36 (75) 12 (25)
3 47 (57.3) 35 (42.7)
4 1 (100) 0
N stage 0.012
0 11 (73.3) 4 (26.7)
1 57 (72.2) 22 (27.8)
2 18 (45) 22 (55)
Adjuvant chemotherapy 0.979
no 45 (64.3) 25 (35.7)
yes 41 (64.1) 23 (35.9)
Molecular Therapy: OncolyticsT cells showed tumor killing that resulted in long-term remission and
significantly improved survival in anaplastic thyroid cancer (ATC)
xenograft and ATC patient-derived xenograft (PDX) models.23,24
In this study, we first examined the correlation between ICAM-1
expression and the prognostic outcomes of GC patients, which jus-
tifies ICAM-1 as an immunotherapeutic target for CAR T cell therapy
in GC. The efficacy of ICAM-1 CAR T cells was then evaluated in sys-
temic and peritoneal human GC xenografts. We further explored the
combination of CAR T cell therapy with paclitaxel and interleukin
(IL)-12 release to improve CAR T cell activity against difficult-to-treat
peritoneal GC tumors. In summary, our study has demonstrated588 Molecular Therapy: Oncolytics Vol. 18 September 2020promising activity of ICAM-1 CAR T cells against GC solid tumors,
and potential to improve CAR T cell efficacy by leveraging strategies
to augment T cell functions.
RESULTS
Patient Characteristics and ICAM-1 Expression in Tumor
Tissues
The clinicopathologic parameters of GC patients enrolled in the
CLASSIC trial who underwent radical gastrectomy with or without
adjuvant chemotherapy were analyzed (n = 134; Table 1). Themedian
age was 55 years (range, 20–76 years), with 93 patients (70.1%) being
men. Fifty-four cases (40.3%) were stage II disease and 80 cases
Figure 1. ICAM-1 Expression Is Associated with Poor Prognosis in Gastric Cancer Patients
(A) ICAM-1 expression was graded as negative (0) (i), weak (1, light brown) (ii), moderate (2, brown) (iii) or strong (3, dark brown) (iv). Scale bars, 20 mm. (B and C) Kaplan-Meier
plots indicating a significant difference in disease-free survival (B) and overall survival (C) between ICAM-1 (blue lines) and ICAM-1+ (green lines) gastric cancer patients (n =
134).
www.moleculartherapy.org(59.7%) were stage III disease. Seventy patients (52%) underwent gas-
trectomy only, and 64 patients (48%) received gastrectomy and adju-
vant chemotherapy. Positive ICAM-1 expression (histoscore [H
score] R 10; example images of ICAM-1 immunohistochemistry
[IHC] are shown in Figure 1A) was found in 48 patients (35.8%)
and was associated with a more advanced stage (20.4% in stage II
versus 46.3% in stage III, p = 0.002) and nodal metastasis (26.7% in
N stage 0, 27.8% in N stage 1, and 55% in N stage 2, p = 0.012).
Ten patients (7.4%) were HER2 positive, and only two of them
were ICAM-1 positive. According to the intensity of ICAM-1 stain-
ing, 12 of 54 cases (22.2%) of stage II and 39 of 80 cases (48.8%) of
stage III were intensity 1 or higher (Table S1).
The Prognostic Value of ICAM-1 Expression in GC Patients
We evaluated the association between ICAM-1 expression and sur-
vival. Patients with positive ICAM-1 expression showed significantly
shorter disease-free survival (DFS) than did those who were ICAM-1
negative (5-year DFS rate, 36.1% versus 75.7%, p < 0.001) (Figure 1B).
In addition, ICAM-1 expression was significantly associated with
worse overall survival (OS) (5-year OS rate, 49.7% versus 84.5%,
p < 0.001) (Figure 1C).
ICAM-1 Expression of GC Cell Lines
We selected eight GC cell lines for evaluation of ICAM-1 expression
and as target cells for validation of CAR T cell activity. According to
the molecular subtypes by The Cancer Genome Atlas (TCGA),25,26
SNU-719 and NCC-24 were assigned to the Epstein-Barr virus
(EBV) subtype, SNU-638 and SNU-1 to microsatellite instability
(MSI), MKN-28 and SNU-5 to chromosomal instability (CIN), and
Hs746t and SNU-601 to genomically stable (GS) (Table S2). By Lau-
ren’s classification,27 SNU-1, SNU-5, SNU-601, NCC-24, and Hs746t
were diffuse type, while SNU-638, SNU-719, andMKN-28 were intes-
tinal type. Most GC cell lines were found to have an intermediate to
high level of ICAM-1 expression, except for SNU-1 and SNU-5,
which were negative for ICAM-1 (Figure 2A). Among the sixICAM-1+ GC cell lines, Hs746t showed the highest expression of
ICAM-1, comparable to or slightly higher than ICAM-1 expression
in a control cell line HeLa (106 molecules per cell24). The level of
ICAM-1 expression in SNU-601, SNU719, and NCC-24 was
moderate when compared to other GC cell lines with high ICAM-1
expression. However, there were no associations between the level
of ICAM-1 expression and Lauren’s classification (intestinal type
versus diffuse type) or TCGA genotypes (EBV, MSI, CIN, and GS).
ICAM-1 CAR T Cell Activity against GC Cell Lines In Vitro
Primary T cells from healthy donors were transduced (a schematic di-
agram of CAR vector is shown in Figure 2B) and expanded using an
automated CliniMACS Prodigy system.28 Final CAR T cell products
displayed comparable transduction efficiencies (51% ± 6%) and vary-
ing frequencies of CD4 and CD8 populations (Figure 2C; Table S3).
We used CP1 and CP5 to test the ability of ICAM-1 CAR T cells to
eliminate GC cells in vitro. For the effector-to-target (E:T) testing,
we established target cell lines with stable expression of GFP and
firefly luciferase (FLuc) via transduction with a FLuc-GFP lentivirus
and cytometry-based sorting for GFP+ cells. E:T assays normalized
to non-transduced (NT) cells demonstrated that the lytic activity of
ICAM-1 CAR T cells was dependent on the level of ICAM-1 expres-
sion in target cells, regardless of Lauren’s classification or TCGA ge-
notypes (Figures 2D and 2E). Overall, target cells with high ICAM-1
expression were eliminated more rapidly than cells with moderate
levels of ICAM-1 expression, whereas minimal killing was observed
for cells that were ICAM-1 negative (Figure 2E). In particular,
SNU-638 was the most susceptible to CAR T cells, with approxi-
mately 50% of SNU-638 cells being lysed after 9 h of incubation
with CP1 and CP5. Despite having the highest ICAM-1 expression,
Hs746t displayed a delayed killing by CP5, while its lysis by CP1
was comparable to that of other ICAM-1-high target cells (e.g.,
MKN-28) or slightly slower than that of others (e.g., SNU-638,
NCC-24). SNU-1 and SNU-5 with no ICAM-1 expression
were largely insensitive to CAR T cell cytotoxicity, similar to theMolecular Therapy: Oncolytics Vol. 18 September 2020 589
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www.moleculartherapy.orgICAM-1 293T control cell line. With the exception of Hs746t, cyto-
toxic activities of CP1 versus CP5 were similar against all other GC
cell lines (Figure 2D).
ICAM-1 CAR T Cell Activity against Systemic GC Xenografts in
Mice
Prior to testing CAR T cell activity against GC xenografts in mice, we
first examined the rate of tumor growth and engraftment patterns af-
ter intravenous (i.v.) versus intraperitoneal (i.p.) injections of GC cell
lines. All eight cell lines exhibited robust engraftment in the perito-
neal cavity after i.p. injection, confirmed by the growth of distinct
masses detected by bioluminescence. In comparison, i.v. injection
of cell lines led to two distinct growth patterns, one defined by
engraftment in the lungs followed by growth in the peritoneum
(SNU-601, MKN-28, SNU-719, and Hs746t) and the other by a
growth in the peritoneal cavity only (SNU-638, SNU-5, NCC-24,
and SNU-1) (Table S2). Hs746t was chosen for a systemic xenograft
model due to its consistent engraftment in the thoracic cavity and
high ICAM-1 expression (Figure 2A). Mice were xenografted by
tail-vein injection of Hs746t cells (1.5  106 cells) and 8 days later
were treated with either NT T cells (donor-matched NT, 10  106
cells, n = 4), ICAM-1 CAR T cells (CP5, 10  106 cells, n = 6), or
left untreated (no treatment [no T], n = 4). In untreated mice or
mice treated with NT cells, tumors continued to grow in the lungs
and subsequently in the peritoneal cavity, causing death within
90 days after xenograft (Figures 3A and 3D). In comparison, mice
treated with CAR T cells exhibited complete remission within 2 weeks
of treatment, which lasted for variable times. However, tumor relapse
in the CAR T cell cohort eventually occurred in two of the six animals.
There was no obvious indication of toxicity in CAR T cell-treated
mice, as assessed by no significant change in body weight (Figure 3C)
and no sign of distress. However, two of the four tumor-free mice
began to show signs of graft-versus-host disease (GvHD) starting
7–8 weeks after treatment, evidenced by weight loss, ruffled fur,
and alopecia, and eventually expired without evidence of tumor
relapse. Overall, the CAR T cell cohort displayed a significantly longer
survival than did the no T or NT treatment cohorts (Figure 3D, p <
0.05). Positron-emission tomography (PET)/computed tomography
(CT) imaging using a SSTR2 tracer, 18F-1,4,7-triazacyclononane-
1,4,7-triacetic acid-octreotide (NOTAOCT),24 revealed the expansion
of ICAM-1 CAR T cells in the lungs where tumor growth was
observed by bioluminescence imaging (Figure 3E). Importantly,
CAR T cells gradually contracted after eliminating tumors, as evi-Figure 2. Correlation of ICAM-1 Expression with CAR T Cell Cytotoxicity in GC
(A) Flow cytometry histograms of ICAM-1 expression in ICAM-1 293T, ICAM-1+ HeLa, a
SSTR2was introduced after CAR and a ribosome skipping porcine teschovirus-1 2A (P2
SS, signal sequence; TM, transmembrane; Cyt, cytoplasmid domain; EF1a, elongation
Myc and anti-SSTR2 antibodies. CD4/CD8 T cell subsets were determined with an anti-h
of target cells by ICAM-1 CAR T cells from two different donors (CP1 and CP5) at a
bioluminescence intensity normalized to the level of target cells co-cultured with non-t
target cell killing at 24 h based on Lauren’s classification, TCGA genotypes, or ICAM-1
experiments with CP1 and CP5 as described in (D). Each value represents mean of triplic
one-way ANOVA. ***p < 0.001. ns, not significant.denced by decreasing PET signals in the lungs and lymph nodes
over time. In contrast, untreated mice or mice treated with NT cells
without SSTR2 expression showed no tracer retention in the lungs.
A background signal of 18F-NOTAOCT was seen in the kidneys
and bladder due to renal clearance, and less intensely in the gall-
bladder and intestinal track caused by hepatobiliary clearance.29
ICAM-1 CAR T Cell Activity against i.p. GC Xenografts in Mice
After validation of potent GC tumor elimination following i.v. injec-
tion of CAR T cells, we then examined CAR T cell efficacy against tu-
mors developed in the peritoneal cavity. Peritoneal dissemination is
the most common pattern of recurrence or metastasis in GC and is
associated with poor prognosis.30 For an i.p. xenograft model, we
chose SNU-638 for its aggressive growth in the peritoneal cavity
and sensitivity to CAR T cells in vitro (Figure 2D). Mice were xeno-
grafted i.p. with SNU-638 cells (3 106 cells) and treated 5 days post-
xenograft with either NT cells, CAR T cells (CP1), or left untreated
(no T) (Figure 4A). To examine differences in CAR T cell efficacy
by the route of injection, T cells were injected into mice 5 days after
tumor injection via either the tail vein or i.p. cavity at two different
doses (low dose, 1  106 CAR T cells; high dose, 10  106 CAR
T cells). All untreated mice and the cohorts of i.v. and i.p. NT cell
treatments showed continued tumor expansion and expired within
45 days of xenograft (Figures 4B and 4D). In comparison, CAR
T cell-treated mice exhibited lower tumor burden and survived longer
than did the no T or NT cell cohorts. i.p. delivery of CAR T cells re-
sulted in a more pronounced treatment effect and survival benefit
over i.v. delivery (Figures 4C and 4D). In the cohort treated with
high-dose i.p. CAR T cells, the tumors seemed to be almost
completely eradicated at 9 days post-xenograft; however, tumor
relapse occurred as early as 2 weeks after complete response in
most mice. The loss of body weight overall was caused by an increase
in tumor burden (Figure 4E).
Ex Vivo Validation of CAR T Cell Tumor Infiltration
Ex vivo images of the gastrointestinal organs further validated the
treatment effect of CAR T cells against SNU-638 peritoneal tumors.
In untreated mice, tumors appeared to form multiple lesions along
the intestinal tract, identifiable by GFP imaging (Figure 4F). In com-
parison, tumor lesions in the intestinal tract of CAR T cell-treated
mice were less frequent and smaller. IHC analysis of tumor nodules
from the mice treated with ICAM-1 CAR revealed CD3+ T cells infil-
trating GFP+ tumors (Figure 4G). Close inspection of the imageCell Lines
nd GC cell lines. (B) Schematic diagram of the ICAM-1 CAR lentiviral vector. Human
A) sequence for PET imaging of CAR T cell biodistribution. LTR, long terminal repeat;
factor 1a. (C) Flow cytometry plots showing CAR expression determined by anti-c-
uman CD3/CD4/CD8 antibody cocktail. (D) Effector-to-target assay measuring lysis
n effector-to-target ratio of 2.5:1. The percentage of live cells was measured by
ransduced T cells. Data represent mean ± SD of triplicate wells. (E) Comparison of
expression (with inclusion of 293T and HeLa controls). Results were pooled from
ate wells. Statistical significance was determined by an unpaired, two-tailed t test or
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Figure 3. Efficacy of ICAM-1 CAR T Cells in a Systemic Xenograft Model
(A) Whole-body bioluminescence images of Hs746t-engrafted NSG mice without treatment (no T), or treated with either NT or ICAM-1 CAR T cells (CP5). (B) Quantitation of
total body bioluminescence (n = 4–6 mice per cohort). Thick lines indicate mean bioluminescence intensity, while thin lines represent data for each individual mouse. (C)
Summary of body weight changes over time. Data represent mean ± SD (n = 4–6). (D) Kaplan-Meier survival curves (log-rank [Mantel-Cox] test; *p < 0.05, **p < 0.01). (E)
Representative PET/CT (coronal view of 20-mm-thick plane, maximum intensity projection) images showing 18F-NOTAOCT uptake inmice left untreated or treated with either
NT or ICAM-1 CAR T cells.
Molecular Therapy: Oncolyticsrevealed the snapshot of CAR T cell activity against tumors: the area
with high CD3 density appeared to be largely devoid of tumor cells,
while the area with sparsely distributed CD3 cells still contained a
high density of tumor cells. In the spleen of the same mice, CD3+ hu-
man T cells were observed in high abundance even at 80 days after
T cell infusion.
Combined Treatment of CAR T Cells with Paclitaxel in an i.p.
Xenograft Model
Although ICAM-1 CAR T cells administered i.p. at a high dose ap-
peared to have a survival benefit, the efficacy was modest and
short-lived, and most treated animals eventually succumbed to tumor
relapse and death. To examine whether the lower tumor burden at the
time of CAR T cell treatment would lead to a better outcome, we first
developed peritoneal tumors at different doses of SNU-638 cells
(0.1  106, 0.5  106, or 3  106 cells per mouse) and analyzed the592 Molecular Therapy: Oncolytics Vol. 18 September 2020survival rate of each cohort. As expected, non-obese diabetic
(NOD) severe combined immunodeficiency (SCID) gamma (NSG)
mice survived proportionally longer when the xenograft dose was
reduced (Figure 5A). In addition to reducing the xenograft dose to
0.1  106 SNU-638 cells, we explored the combination of CAR
T cell therapy with chemotherapy, which has been shown to sensitize
tumor cells to immunotherapy in preclinical studies.31,32 Among
chemotherapeutic agents, we used paclitaxel, which is the most
commonly used agent in advanced GC as a second-line therapy.33
In murine models, paclitaxel has been previously used, ranging up
to 75 mg/kg for i.p. injection.34 In a pilot study, a weekly i.p. injection
of 20 mg/kg paclitaxel for 3 weeks led to frequent severe toxicities or
death (four out of six mice), while a dose of 10 mg/kg of paclitaxel was
found to be well tolerated. For a combination study, a dose of 10 mg/
kg for paclitaxel was chosen for i.p. weekly injection for 3 weeks,
commencing on 2 days prior to CAR T cell infusion, and 5 and
Figure 4. Efficacy of ICAM-1 CAR T Cells in an Intraperitoneal Xenograft Model
(A) Whole-body bioluminescence image of SNU-638-engrafted NSGmice without treatment (no T), or treated with non-transduced T (NT) or low or high doses (LD or HD) of
ICAM-1 CAR T cells. Mice were treated with T cells 5 days after tumor xenograft either by intravenous or intraperitoneal injection. LD, 1 106 CAR T cells; HD, 10 106 CAR
T cells. (B) Quantitation of total body bioluminescence intensity. Data represent mean ± SD (n = 2–3). (C) Bioluminescence intensities on day 33 following xenograft. LD and
HD cohorts were pooled for analysis. An unpaired, two-tailed t test was used for statistical comparisons. *p < 0.05, **p < 0.01. ns, not significant. (D) Kaplan-Meier survival
curves. (E) Summary of body weight changes over time. Data represent mean ± SD (n = 2–3). (F) GFP images of tumors and gastrointestinal tracts acquired on day 85 post-
xenograft. (G) Histologic images of H&E staining, GFP IHC, and CD3 IHC of tumor or spleen from mice treated with ICAM-1 CAR T cells.
www.moleculartherapy.org12 days after infusion of CAR T cells. The cohorts of either T cells
alone or T cells in combination with paclitaxel were infused with
NT versus CAR T (CP1, 10  106) cells i.p. 7 days after tumor xeno-
graft (n = 5 for each group; Figure 5B). Compared to the cohorts of no
T or NT cells, paclitaxel monotherapy or paclitaxel with NT cells sup-
pressed tumor growth; however, tumors reappeared once the treat-
ment with paclitaxel ended. CAR T cell therapy alone produced com-
plete to partial responses, which lasted for variable times before
tumors began to grow back in most mice. In comparison, the combi-
nation therapy with CAR T cells and paclitaxel led to the most potent
suppression of tumor growth, attaining complete response in two outof five mice. However, mice with tumor suppression in this cohort
eventually succumbed to the regrowth of tumors (Figure 5B). Overall,
the combination cohort achieved the longest survival, while CAR
T cells alone, paclitaxel monotherapy, and paclitaxel with NT cohorts
produced survival benefit only slightly better than the no T or NT
cohort (Figure 5D). PET/CT imaging with 18F-NOTAOCT taken at
8 weeks after T cell injection confirmed the expansion and localiza-
tion of CAR T cells in the lungs and even in peritoneal cavity, judging
from significantly higher tracer uptake in the lower body compared to
the levels seen in control mice (peritoneal areas other than kidneys
and bladder in Figure 5E versus no T or NT mice in Figure 3B).Molecular Therapy: Oncolytics Vol. 18 September 2020 593
Figure 5. Superior Efficacy of Combination Treatment of ICAM-1 CAR T Cells with Paclitaxel in an Intraperitoneal Xenograft Model
(A) Kaplan-Meier survival curves of untreated NSG mice intraperitoneally xenografted with different doses of SNU-638 cells (log-rank [Mantel-Cox] test; **p < 0.01; ns, not
significant). (B) Whole-body bioluminescence images of SNU-638-engrafted NSG mice received either no treatment, or monotherapy with either T cells or paclitaxel, or
combinatorial treatment. (C) Quantitation of total body bioluminescence intensity. Data represent mean ± SD (n = 5). (D) Kaplan-Meier survival curves (log-rank [Mantel-Cox]
test; *p < 0.05, **p < 0.01; ns, not significant). (E) Representative PET/CT images of mice treated with ICAM-1 CAR T cells on 9 weeks post-xenograft (8 weeks after T cell
injection). Coronal view of PET/CT images pseudo-colored with PET maximum intensity projection over a 20-mm-thick plane.
Molecular Therapy: OncolyticsDespite potential cytotoxic effects of paclitaxel on CAR T cells (Fig-
ure S1), our imaging supports the ability of CAR T cells to recover
and persist in mice even after repeated administration of paclitaxel.
Inducible IL-12 Boosts CAR T Cell Activity against Peritoneal GC
Tumors
As an alternative to combining CAR T cells with chemotherapy, we
explored the incorporation of inducible cytokines into the CAR vec-
tor to promote CAR T cell proliferation and effector functions, and to
improve CAR T cell activity against peritoneal tumors. We designed a
lentiviral vector that incorporates the expression cassettes for CAR
and CAR activation-dependent IL-12 to support the cytotoxic activity
and survival of T cells and the T helper (Th)1 T cell response (Fig-
ure 6A).35,36 In order to locally deliver IL-12 upon CAR activation
in the targeted tumor lesions while avoiding systemic toxicity that
has been observed with constitutive secretion or systemic administra-
tion of IL-12,37–39 an inducible IL-12 gene was placed downstream of
the synthetic promoter containing both a nuclear factor kB (NF-kB)-
responsive promoter and IL-2 minimal promoter with six repeated
binding sites for nuclear factor of activated T cells (NFAT) (desig-
nated as the NF-kB-NFAT promoter). An inducible GFP construct
was also designed to validate the specificity of the NF-kB-NFAT pro-
moter upon target cell stimulation. In Jurkat T cells transduced with
ICAM-1 CAR/GFP, GFP expression was seen after co-incubation for
24 h at 37C with human ICAM-1-transduced 293T cells (Figure 6B).
Similarly, ICAM-1 CAR/IL-12 T cells secreted elevated levels of IL-12
after co-incubation with ICAM-1+ 293T cells or the addition of phor-594 Molecular Therapy: Oncolytics Vol. 18 September 2020bol myristate acetate (PMA)/ionomycin to media, but not with
ICAM-1 293T cells, indicating that IL-12 secretion was specific to
CAR signaling (Figure 6C). From the E:T assay measured at 24 h after
incubation of target cells with T cells at a 1:1 ratio, CAR/IL-12 T cells
mediated significantly higher killing of ICAM-1+ HeLa and SNU-638
cells compared to CAR T cells without IL-12 release (Figure 6D).
Cytotoxicity of IL-12-armored CAR T cells was ICAM-1-dependent
with minimal killing of ICAM-1 293T cells. To compare the treat-
ment efficacy in vivo, donor-matched CAR T (CP9, 15  106 total
cells) and CAR/IL-12 T cells (15  106 total cells) were administered
to mice i.p. 1 week after an i.p. xenograft with 0.5  106 of SNU-638
cells. Whole-body bioluminescence imaging revealed that CAR/IL-12
T cells reduced the tumor burden significantly more compared to un-
treated control or CAR T cells (Figures 6E and 6F). We collected pe-
ripheral blood at 2, 3, and 6 weeks after tumor xenograft to determine
cytokine levels and the abundance of circulating T cells. As expected,
IL-12 was detected only in the blood of mice treated with CAR/IL-12
T cells, which gradually increased to 1 ng/mL (Figure 6G). The
improved tumor-lytic capacity of CAR/IL-12 in vivo was also accom-
panied with increased levels of serum interferon (IFN)-g and tumor
necrosis factor (TNF)-a (Figure 6G). Peripheral blood collected at
5–8 weeks after tumor xenograft revealed significant expansion of
CD3+ T cells after treatment with CAR/IL-12 T cells compared to
treatment with CAR T (CP9) cells (79.4% versus 19%) (Table S4).
However, greater expansion of CD3+ T cells due to IL-12 secretion
was not limited to CAR-transduced T cells (8% CAR positive in
pre-infusion [Table S3] and 13% CAR positive in post-infusion
Figure 6. Inducible IL-12 Release Augments Antitumor Activity of CAR T Cells in a GC Peritoneal Tumor Model
(A) Schematic diagram of the lentiviral vector encoding inducible IL-12. The expression of ICAM-1 CAR is driven by the EF1a promoter, while IL-12 expression is under the
transcriptional control of a synthetic NF-kB-NFAT promoter. (B) GFP expression in Jurkat CAR/GFP T cells after coculture for 24 h with 293T cells with or without human
ICAM-1 (hICAM-1) expression. CAR expression was estimated by staining with an anti-SSTR2 antibody. (C) IL-12 release by Jurkat CAR/IL-12 T cells after coculture with
293T cells with or without human ICAM-1 expression, or with the addition of PMA and ionomycin to media, measured in duplicate (mean ± SD). (D) Comparison of target cell
lysis by CAR T (CP9) and CAR/IL-12 T cells during 24 h at an E:T ratio of 1:1. Data represent mean ± SD (n = 4; unpaired, two-tailed t test; ****p < 0.0001; ns, not significant).
(E) Whole-body bioluminescence images of NSG mice xenografted with 0.5  106 SNU-638 (two independent experiments, n = 6–7 per cohort). (F) Quantitation of
bioluminescence intensity over time (n = 6–7 per cohort). Each line represents data for each individual mouse. (G) Cytokine levels in the plasmaweremeasured from the blood
collected at 2, 3, and 6 weeks post-xenograft. Data represent mean ± SD (n = 1–2).
www.moleculartherapy.org[Table S4]), alluding to the systemic effect of IL-12, causing an expan-
sion of all T cells. Collectively, our findings highlight the superior
anti-tumor activity of CAR/IL-12 T cells against difficult-to-treat
peritoneal tumors.
DISCUSSION
Currently, the treatment options for GC patients with locally
advanced and metastatic disease are very limited, with a median sur-
vival of less than 1 year. Moreover, systemic and targeted therapies for
peritoneal disease have very poor efficacy.8 In this study, we examinedthe therapeutic potential of CAR T cells targeting ICAM-1 in preclin-
ical models of systemic and i.p. metastases of GC. Overall, a single
infusion of ICAM-1-targeting CAR T cells was found to potently
eliminate tumors generated in mice via i.v. injection that initiated tu-
mor growth in the lungs. This is similar to the efficacy of ICAM-1-tar-
geting CAR T cells observed against systemic ATC in our previous
studies,23 providing a further proof of concept for this treatment mo-
dality against systemic tumors with high levels of ICAM-1 expression.
In comparison, the same CAR T cells, delivered either i.v. or i.p., were
less effective against tumors injected directly into the peritoneal cavityMolecular Therapy: Oncolytics Vol. 18 September 2020 595
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membrane. The lower activity of CAR T cells against peritoneal tu-
mor lesions is likely due to limitations hindering CAR T cell therapy
against solid tumors, which include challenges to tumor penetration,
an immune-suppressive milieu, and maintaining T cell activity in
hypoxic and nutrient-depleted surroundings.40–42
We have chosen ICAM-1 as a target for our CAR T cells against GC
based on the finding that ICAM-1 expression was seen in approxi-
mately 40% of the GC patients enrolled in a prospective trial,43 and
it was directly associated with lymph nodemetastasis and higher stage
disease. GC patients with positive ICAM-1 expression also showed
significantly shorter OS and DFS. However, ICAM-1 expression
has also been reported by others to be inversely correlated with the
incidence of lymph node or distant metastases in colorectal, gastric,
and breast cancer patients, and to be associated with a better
prognosis.44–46 In one scenario, ICAM-1 expression in tumors may
stimulate interaction with the immune cells via ICAM-1 interaction
with integrins, including LFA-1,47 and boost immune surveillance.
In contrast, ICAM-1 expression has also been observed in malignant,
dedifferentiated tumors, including thyroid and breast cancers, as well
as cancer stem cells.23,48–50 The reason for the discrepancy in the role
of ICAM-1 on tumor growth and metastasis is unclear. It is possible
that ICAM-1 expression at an early stage of tumor development may
suppress tumor growth by elevating immune surveillance, while at a
later stage ICAM-1 is further induced with tumor malignancy and
loss of differentiation.
Aiming at achieving optimal response while avoiding toxicity toward
normal cells with basal levels of ICAM-1 expression, in this study, we
used affinity-tuned ICAM-1 CAR T cells (equilibrium dissociation
constant [KD] of 20 mM).24 The use of low-affinity CAR against
target antigen resulted in the lytic activity of CAR T cells to be in
strong correlation with the level of ICAM-1 expression in GC cell
lines in vitro. CAR T cells targeting other antigens, such as HER2,
CEA, EpCAM, MSLN, and CLDN18.2, are being tested in gastric
and colorectal cancer patients. Early clinical study of HER2 CAR
T cells against metastatic colon cancer showed fatal on-target off-tu-
mor toxicities mediated by recognition of HER2 in non-malignant
pulmonary tissue.51 However, the newer generation of HER2 CAR
T cells with lower affinity was well tolerated with no dose-limiting
toxicity, although the treatment benefits were not obvious in
HER2+ malignancies, including sarcoma and glioblastoma.14,52
CEA-targeting CAR T cells mediated tumor remission and inhibited
tumor growth after re-challenges in preclinical colorectal peritoneal
carcinomatosis models.15 This study has shown that a regional i.p.
infusion resulted in superior anti-tumor response than did systemic
delivery of CAR T cells. i.p. infused CEA CAR T cells are currently
being studied in patients with CEA-expressing peritoneal metastases
(ClinicalTrials.gov: NCT03682744).
Eight different GC cell lines developed tumors intrathoracically, i.p.,
or both when injected intomice i.v. via the tail vein. In comparison, all
i.p. injections of cell lines led to tumor growth in the peritoneal space.596 Molecular Therapy: Oncolytics Vol. 18 September 2020The efficacy of ICAM-1-targeting CAR T cells was then evaluated in
two different xenograft models, that is, an intrathoracic tumor growth
model using the Hs746t cell line and i.p. tumor growth using SNU-
638. In the intrathoracic xenograft model, the systemic administra-
tion of CP5 CAR T cells achieved a durable response with a 60%
cure rate. Although CP5 cytotoxic activity against Hs746t seemed
to be modest with a delay in the onset of killing in vitro, its activity
in vivo was rapid, as demonstrated by complete tumor elimination
within 2 weeks of treatment.
In the i.p. metastasis model, we compared the efficacy of CAR T cells
delivered via the tail vein versus direct injection into the i.p. cavity.
Similar to the previous report that intrapleural or i.p. injection of
CAR T cells showed higher efficacy than did systemic administration
against various tumor xenografts,15,53,54 we observed a significantly
higher tumor response to CAR T cells delivered i.p. This is likely
due to the ability of T cells to traffic more effectively and accumulate
in the peritoneal space in higher numbers. However, despite the
higher efficacy and longer survival after i.p. CAR T cell delivery, the
overall response of peritoneal tumors was more modest compared
to the response of tumors growing in the lungs. Incomplete response
of CAR T cells against i.p. tumors was not due to a lack of CAR T cell
persistence, as evidenced by histologic confirmation and PET/CT
detection of CAR T cells in the body, including peritoneal space,
lung, spleen, and lymph nodes. As shown from immunostaining of
tumor tissues, the presence of sparsely distributed, single T cells inter-
spersed among tumor cells may allude to the suppression of CAR
T cell activity and proliferation by the tumor environment surround-
ing T cells.55
Preclinical studies have demonstrated that chemotherapy can sensi-
tize tumor cells to immunotherapy, likely by improving tumor anti-
gen recognition and inhibiting suppressive immune cells.31,32,56 In
addition, CAR T cell therapy after conditioning chemotherapy has
shown a better response rate and greater CAR T cell expansion.57,58
Therefore, we tested the combined treatment of paclitaxel and
ICAM-1 CAR in an SNU-638 i.p. tumor model. Paclitaxel has been
used as a standard second-line chemotherapy in GC worldwide,33
and it has a highly favorable concentration ratio of i.p. to plasma
and remarkable drug penetration into cells.59 Monotherapy with
paclitaxel or CAR T cells suppressed tumor growth at the early stage,
yet tumor relapse eventually occurred in most animals. For the com-
bination therapy, paclitaxel was given three times, 2 days prior to, as
well as 5 and 12 days after CAR T cell infusion. The cytotoxic effect of
paclitaxel would therefore not only be on tumor cells but also on CAR
T cells, potentially limiting the full benefit of combination therapy.
Paclitaxel was indeed confirmed to significantly reduce T cell prolif-
eration in vitro at a dose (10mg/kg, which is approximately 15–20 mM
assuming 60% body weight being paclitaxel-accessible fluid) that
would mimic the concentration of paclitaxel that T cells are exposed
to (Figure S1). Despite potential cytotoxic effects by paclitaxel, CAR
T cells appeared to have recovered and expanded, evidenced by
PET/CT imaging of CAR T cell presence in the body. Therefore,
incomplete elimination of tumor by combination therapy is not due
www.moleculartherapy.orgto a lack of CAR T cell persistence, but more likely due to immune-
suppressive effects caused by tumor growth. Our future studies will
further explore optimization of the dose and frequency of CAR
T cells and paclitaxel administration in order to further maximize
the efficacy of combination therapy.
To improve the efficacy of CAR T cell treatment in solid tumors, com-
bination therapy with other immunotherapeutic modalities, such as
immune checkpoint inhibitors,60,61 oncolytic virus,62,63 and vac-
cines,64,65 has also been shown to improve the efficacy of CAR
T cells. Some of these approaches are being used in clinical trials
and may overcome the current problems encountered in the setting
of solid tumors. One alternative approach is arming CAR T cells
with T cell-activating cytokines, including IL-12, IL-7/CCL19, IL-
15, IL-18, and IL-23.66–70 These cytokines were found to differentially
affect T cell phenotype, persistence, and proliferation, and to improve
CAR T cell treatment. IL-12-producing CAR T cells in particular re-
sulted in longer survival and increased tumor cytotoxicity in preclin-
ical models.66,71,72 Besides promotion of Th1 phenotype and expan-
sion of T cells, IL-12 can augment CAR T cell activity by
suppressing PD-1 upregulation, which is induced by T cell activa-
tion.73 Compared to prior studies of arming CAR T cells with consti-
tutive expression of IL-12, we have designed our CAR T cells to
release IL-12 in a manner dependent on T cell activation. The
sequence or the number of repeats of NF-kB and/or NFAT binding
motifs may be optimized to reduce the level of inducible cytokine
secretion to further enhance safety. However, the mouse model
used in this study, i.e., the use of human tumor and T cells in an im-
mune-compromised NSG strain, is inadequate to fully evaluate po-
tential toxicity arising from IL-12. This is partly due to the fact that
human IL-12 and IFN-g do not cross-react with murine receptors.74
Furthermore, xenogeneic transplants of human T cells into immuno-
deficient NSG mice invariably cause GvHD in time due to the recog-
nition of mouse peptide/major histocompatibility complex (MHC) by
human T cell receptor (TCR).75 We speculate that a huge spike in IL-
12 release and T cell expansion of our CAR/IL-12 T cells may have
been caused by xenogeneic TCR activation and subsequent activation
of NF-kB-NFAT promoter and IL-12 release. Additional evidence for
this hypothesis was seen in a subcutaneous thyroid cancer model
(ATC23): low IL-12 levels (<250 pg/mL) were measured until tumor
was completely eliminated, followed by a sudden spike of IL-12
(2 ng/mL) coincident with the onset of GvHD symptoms such as
weight loss and ruffled fur (Figure S2). The use of a mouse strain
that is less prone to GvHD (e.g., an MHC class I- and MHC class
2-deficient strain76) or mouse CAR T cells with inducible IL-12 in
an immune-competent strain77 will be beneficial to further optimize
cytokine delivery in conjunction with CAR, prior to ultimately testing
the risks and benefits of arming CAR T cells with cytokine secretion to
treat human patients.
The characteristics of pre-infusion CAR T cells can significantly
impact CAR T cell efficacy in vivo. For instance, a comprehensive
analysis of intrinsic CD19 CAR T cell characteristics has revealed
that pre-infusion CAR T cell fitness can be a predictive marker of clin-ical response.78 This study has shown that a higher CAR T cell po-
tency in mice, T cell memory-related gene signature, and specific
T cell subsets (CD27+PD-1CD8+) were found to correlate with clin-
ical response. In our study, we used three batches of CAR T cells (CP1,
CP9, and CAR/IL-12 T cells) produced from the blood of two
different donors to evaluate CAR T cell activity against an i.p. xeno-
graft, and one batch of CAR T (CP5) cells against a systemic xeno-
graft. Given the significant difference in the CD4-to-CD8 ratios
among these batches (Table S3) and other characteristics that have
not been examined in this study, it is possible that the tumor response
to CAR T cells may vary significantly from batch to batch. Despite
some notable differences in T cell characteristics, however, our previ-
ous study has demonstrated fairly homogeneous activity of six
different CAR T cell batches against advanced thyroid cancer cells
in vitro and in vivo.28 Clearly, such a homogeneous response in a pre-
clinical model is greatly ascribed to the use of healthy donor blood for
CAR T cell manufacturing, and the use of a mouse model with tumor
xenograft.
In conclusion, we have demonstrated a robust response to ICAM-1
CAR T cell monotherapy against systemic metastases using a GC
mouse model. In addition, combination with paclitaxel was found
to significantly enhance the treatment effect of CAR T cells in the
more refractory peritoneal GC metastasis model. When our ICAM-
1 CAR T cells were armored with inducible IL-12, the treatment effect
was also more pronounced against peritoneal metastatic gastric tu-
mors, accompanied with higher levels of IFN-g and TNF-a detected
in plasma. Our study warrants the development of ICAM-1 CAR




To investigate ICAM-1 expression in tumor tissues of GC patients, we
evaluated the tumor tissues of patients who were enrolled in the
CLASSIC trial in Yonsei Cancer Center, Seoul, Korea.3 All patients
had undergone radical gastrectomy with D2 lymph node dissection
for primary gastric tumors and were randomized to treatments
with adjuvant chemotherapy or surgery alone, according to the
CLASSIC protocol. The current study included 134 patients with
stage II–III malignancies, based on the Sixth Edition of the American
Joint Committee on Cancer/Union for International Cancer Control
guidelines.79 Informed consents for the CLASSIC trial were obtained
from all patients. Since this study was performed more than 5 years
after the CLASSIC trial was finished, additional informed consents
were waived by the Institutional Review Board (IRB) of Severance
Hospital (IRB no. 4-2017-1111).
IHC Analysis
ICAM-1 expression in human tissue was evaluated by IHC using an
anti-ICAM-1 antibody (G-5, Santa Cruz Biotechnology). Scoring was
performed by an independent pathologist blinded to the patients’
clinical information. Protein expression was interpreted by the
weighted histoscore method (H score).80 The intensity of proteinMolecular Therapy: Oncolytics Vol. 18 September 2020 597
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(dark brown). The final score was calculated as follows: (0  % of
negative cells) + (1%of light brown cells) + (2%of brown cells) +
(3  % of dark brown cells). Tumors with an H score of equal to or
more than 10 were defined as positive ICAM-1 expression, while tu-
mors with a score of less than 10 were defined as negative ICAM-1
expression. HER2 expression was analyzed by IHC using a HercepT-
est kit (Dako, Denmark), fluorescence in situ hybridization (FISH)
using a Vysis HER2/CEP17 FISH probe kit (Abbott, USA) and a
Dako detection kit (Dako, Denmark), and silver-enhanced in situ hy-
bridization (SISH) using the Ventana Discovery XT system (Ventana/
Roche, USA) according to the manufacturers’ instructions. FISH and
SISH scores were assessed by detecting the fluorescence signal in 50
malignant cell nuclei. HER2 positivity was defined as either HER2
IHC 3+ or IHC 2+ and FISH/SISH positive (HER2/CEP17 [centro-
mere enumerator probe 17] R 2).
Cell Culture
We evaluated eight GC cell lines for ICAM-1 expression. HeLa and
HEK293T cell lines were used as positive and negative controls for
ICAM-1 CAR, respectively. SNU series and MKN-28 were obtained
from the Korean Cell Line Bank (Seoul National University, Seoul,
Korea), while Hs746t, HeLa, and HEK293T cells were obtained
from the American Type Culture Collection (ATCC, Manassas,
VA, USA). All target cells were transduced with lentivirus encoding
FLuc-F2A-GFP (Biosettia), and GFP-expressing cells were isolated
by fluorescence-activated cell sorting (FACS). All cells were main-
tained in RPMI 1640 medium (Lonza, Walkersville, MD, USA) sup-
plemented with 10% fetal bovine serum (Omega Scientific, Tarzana,
CA, USA) and cultured in a humidified incubator at 37C with 5%
CO2.
CAR T Cell Manufacturing
ICAM-1 CAR T cells were manufactured using the automated Clin-
iMACS Prodigy (Miltenyi Biotec) as described previously.28 ICAM-1
CAR T cells manufactured from three different donors were desig-
nated as CP1, CP5, and CP9, respectively. ICAM-1 CAR T cells
with inducible IL-12 were produced from the same donor as CP9
and manufactured using a 50-mL bioreactor tube (TubeSpin, TPP)
on a bottle roller (Thermo Scientific) housed in a humidified incu-
bator. Briefly, primary human T cells were transduced with lentivirus
twice at 24 and 48 h after activation with anti-CD3/CD28 Dynabeads
(Gibco). T cells were expanded for 10 days in TexMACS GMP (good
manufacturing process) medium (Miltenyi Biotec) supplemented
with 5% human AB serum (Sigma-Aldrich), 12.5 ng/mL IL-7 (Milte-
nyi Biotec), and 12.5 ng/mL IL-15 (Miltenyi Biotec). Cell products
were cryopreserved on day 10 in a 1:2 mixture of T cell complete
growth medium and CS10 (STEMCELL) for in vitro and in vivo
experiments.
Flow Cytometry Analysis
Live cells were gated by calcein blue (Thermo Fisher Scientific) and
stained with fluorophore-conjugated antibodies. ICAM-1 expression
in GC cell lines was determined by staining with 5 mg/mL of allophy-598 Molecular Therapy: Oncolytics Vol. 18 September 2020cocyanin (APC)-conjugated ICAM-1 antibody (clone HA58, Bio-
Legend). CAR expression was detected by fluorescein isothiocyanate
(FITC)-conjugated anti-c-Myc antibody (clone SH1-26E7.1.3, Milte-
nyi Biotec). SSTR2 expression was detected by APC-conjugated anti-
human SSTR2 antibody (clone 402038, R&D Systems). T cell prod-
ucts were also analyzed with a cocktail of anti-human phycoerythrin
(PE)/Cy5-CD3, PE-CD4, and FITC-CD8 antibodies (clone UCHT1,
RPA-T4, RPA-T8, BioLegend).
In Vitro Measurements of Inducible GFP and IL-12 Expression
To monitor inducible GFP and IL-12 expression upon CAR stimula-
tion, Jurkat CAR T cells (5 104 Jurkat T cells per well) were co-incu-
bated with 293T cells with or without human ICAM-1 (hICAM-1)
expression at an E:T ratio of 1:1, or activated with 10 ng/mL PMA
and 500 ng/mL ionomycin. GFP expression was analyzed by flow cy-
tometry, and IL-12 secretion in the culture supernatant was detected
by Bio-Plex MAGPIX (Bio-Rad) following the manufacturer’s
instructions.
E:T Assay
Target cells (5 103) with FLuc expression were co-cultured with NT
T cells or CAR T cells at the indicated E:T ratios in T cell media con-
taining 150 mg/mL D-luciferin (Gold Biotechnology) with no cytokine
supplement. Luminescence values were measured using a plate reader
(Tecan Infinite M1000PRO), and the values of luminescence were
normalized to the NT-treated target cells.
Animal Study
Animal studies were approved by Weill Cornell Medicine’s Institu-
tional Animal Care and Use Committee. For the i.v. xenograft model,
Hs746t cells were injected into 4- to 6-week-old male NSG mice
(Jackson Laboratory) via the tail vein. Treatment cohorts consisted
of no T, NT, or ICAM-1 CAR. NT and ICAM-1 CAR were injected
via the tail vein 8 days after tumor cell injection. SNU-638 cells
were used for the i.p. xenograft model. For combination treatment
with paclitaxel in the i.p. xenograft model with SNU-638, paclitaxel
was administered i.p. once a week at 10 mg/kg for 3 weeks. In the
inducible IL-12 ICAM-1 CAR T cell study, NSG mice bearing perito-
neal SNU-638 tumors were left untreated (no T) or treated i.p. with
CAR T cells with and without IL-12 release on day 7 following tumor
xenograft. Luminescence imaging was performed weekly using a
whole-body optical imager (In-Vivo Xtreme 4MP, Bruker; or in vivo
imaging system (IVIS) Spectrum, PerkinElmer) 15 min after subcu-
taneous injection of 200 mL of 15 mg/mL D-luciferin (GoldBio) in
live xenograft mice under anesthesia using 2% isoflurane in 2 L/
min O2. PET/CT was performed as described previously
24 for the
detection of T cell distribution using a micro-PET/CT scanner (In-
veon, Siemens) at 2 h after 18F-NOTAOCT81 injection. Tracer uptake
was visualized in the unit of % injection dose (ID)/cm3, determined by
the counts in a reference tube.82 Mouse peripheral blood samples
were collected, and serum cytokine levels were measured by Bio-
Plex MAGPIX (Bio-Rad) following the manufacturer’s instruction.
Peripheral blood mononuclear cells (PBMCs) were isolated by Fi-
coll-Paque density gradient centrifugation and analyzed with a
www.moleculartherapy.orgcocktail of anti-human PE/Cy5-CD3, PE-CD4, and FITC-CD8 anti-
bodies (clone UCHT1, RPA-T4, RPA-T8, BioLegend). For survival
studies, mice were euthanized when they had a weight loss of greater
than 30% and exhibited signs of severe illness, including lethargy,
hunched posture, and inactivity. Ex vivo images were obtained using
a whole-body optical imager (In-Vivo F Pro, Bruker). Tumors were
resected and fixed in 10% buffered formalin before being transferred
to 70% ethanol. IHC analysis for CD3 (ab135372, Abcam) and GFP
(A6455, Invitrogen) was performed in xenograft tumor tissues (Mo-
lecular Cytology Core Facility, Memorial Sloan Kettering).
Statistical Analysis
Differences between patients who were positive or negative with re-
gard to ICAM-1 expression were compared using the chi-square or
Fisher’s exact test. DFS was defined as the time from the date of the
operation to the date of recurrence, death, or last follow-up. OS was
defined as the time of operation to the date of death (from any cause),
or last follow-up. DFS and OS were analyzed using the Kaplan-Meier
method and the log-rank test. For in vitro experiments and animal
studies, the values were analyzed by an unpaired, two-tailed Student’s
t test (between two groups) or one-way ANOVA (between three or
more groups). Mouse survival curves were generated using the
method of Kaplan-Meier, and the significance was analyzed with
the log-rank (Mantel-Cox) test. The statistical tests used in each
experiment are indicated in the figure legends. Statistical analyses
were performed using SPSS software (v.23.0, SPSS, Chicago, IL,
USA) and Prism 8 software (GraphPad, San Diego, CA, USA). Differ-
ences with a p value of <0.05 were considered statistically significant.
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